TABLE OF CONTENTS
|  |  |  | Volume 35, Issue 47 (November 2016) |  | In this issue Review Original Articles Corrigenda
Also new    AOP | |  |  | Review | Top |  | Targeting CK2-driven non-oncogene addiction in B-cell tumorsE Mandato, S Manni, F Zaffino, G Semenzato and F Piazza Oncogene 2016 35: 6045-6052; advance online publication, April 4, 2016; 10.1038/onc.2016.86 Abstract | Full Text |  | Original Articles | Top |  | The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironmentJ Turpin, C Ling, E J Crosby, Z C Hartman, A M Simond, L A Chodosh, J P Rennhack, E R Andrechek, J Ozcelik, M Hallett, G B Mills, R D Cardiff, J W Gray, O L Griffith and W J Muller Oncogene 2016 35: 6053-6064; advance online publication, May 9, 2016; 10.1038/onc.2016.129 Abstract | Full Text |  |  |  | Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signalsY Cui, Y Sun, S Hu, J Luo, L Li, X Li, S Yeh, J Jin and C Chang Oncogene 2016 35: 6065-6076; advance online publication, July 4, 2016; 10.1038/onc.2016.135 Abstract | Full Text |  |  |  | Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodiesP Bernasconi-Elias, T Hu, D Jenkins, B Firestone, S Gans, E Kurth, P Capodieci, J Deplazes-Lauber, K Petropoulos, P Thiel, D Ponsel, S Hee Choi, P LeMotte, A London, M Goetcshkes, E Nolin, M D Jones, K Slocum, M J Kluk, D M Weinstock, A Christodoulou, O Weinberg, J Jaehrling, S A Ettenberg, A Buckler, S C Blacklow, J C Aster and C J Fryer Oncogene 2016 35: 6077-6086; advance online publication, May 9, 2016; 10.1038/onc.2016.133 Abstract | Full Text |  |  |  | Leukemic survival factor SALL4 contributes to defective DNA damage repairF Wang, C Gao, J Lu, H Tatetsu, D A Williams, L U Müller, W Cui and L Chai Oncogene 2016 35: 6087-6095; advance online publication, May 2, 2016; 10.1038/onc.2016.146 Abstract | Full Text |  |  |  | Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3′UTR and 5′UTR of Jab1/CSN5S Wang, Y Pan, R Zhang, T Xu, W Wu, R Zhang, C Wang, H Huang, C A Calin, H Yang and F X Claret Oncogene 2016 35: 6096-6108; advance online publication, May 9, 2016; 10.1038/onc.2016.147 Abstract | Full Text |  |  |  | Suppression of intestinal tumors by targeting the mitotic spindle of intestinal stem cellsR Yao, J Oyanagi, Y Natsume, D Kusama, Y Kato, S Nagayama and T Noda Oncogene 2016 35: 6109-6119; advance online publication, May 9, 2016; 10.1038/onc.2016.148 Abstract | Full Text |  |  |  | GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing Wnt/β-catenin signaling in lung adenocarcinomaS Yuan, Z Yu, Q Liu, M Zhang, Y Xiang, N Wu, L Wu, Z Hu, B Xu, T Cai, X Ma, Y Zhang, C Liao, L Wang, P Yang, L Bai and Y Li Oncogene 2016 35: 6120-6131; advance online publication, May 9, 2016; 10.1038/onc.2016.149 Abstract | Full Text |  |  |  | A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancerY Ma, C Yu, E M Mohamed, H Shao, L Wang, G Sundaresan, J Zweit, M Idowu and X Fang Oncogene 2016 35: 6132-6142; advance online publication, May 2, 2016; 10.1038/onc.2016.150 Abstract | Full Text |  |  |  | Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasisM F Montenegro, L Sánchez-del-Campo, R González-Guerrero, E Martínez-Barba, A Piñero-Madrona, J Cabezas-Herrera and J N Rodríguez-López Oncogene 2016 35: 6143-6152; advance online publication, May 2, 2016; 10.1038/onc.2016.154 Abstract | Full Text |  | Corrigenda | Top |  | The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferationC M Das, P Taylor, M Gireud, A Singh, D Lee, G Fuller, L Ji, J Fangusaro, V Rajaram, S Goldman, C Eberhart and V Gopalakrishnan Oncogene 2016 35: 6153-6154; advance online publication, July 18, 2016; 10.1038/onc.2016.141 Full Text |  |  |  | Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcomaS Sankar, R Bell, B Stephens, R Zhuo, S Sharma, D J Bearss and S L Lessnick Oncogene 2016 35: 6155-6156; advance online publication, June 27, 2016; 10.1038/onc.2016.142 Full Text |  |  |  |  |  |  |  |  |  |  | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com |  |  |  |  |  | |  | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |  | | | |
No comments:
Post a Comment